Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups.

Transl Lung Cancer Res · 2024 · PMC11225043 · PMID 38973958

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significanceP=0.18not close (p > 0.1)

Although a trend towards separation between the two survival curves was observed, the difference did not reach statistical significance (HR =0.70, P=0.18, Figure 5D ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.